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Since 1992, the amyloid cascade hypothesis has played the prominent role in explaining the etiology and pathogenesis of
Alzheimer’s disease (AD). It proposes that the deposition of β-amyloid (Aβ) is the initial pathological event in AD leading to the
formation of senile plaques (SPs) and then to neuroﬁbrillary tangles (NFTs), neuronal cell death, and ultimately dementia. While
there is substantial evidence supporting the hypothesis, there are also limitations: (1) SP and NFT may develop independently, and
(2) SPs and NFTs may be the products rather than the causes of neurodegeneration in AD. In addition, randomized clinical trials
that tested drugs or antibodies targeting components of the amyloid pathway have been inconclusive. This paper provides a critical
overview of the evidence for and against the amyloid cascade hypothesis in AD and provides suggestions for future directions.
1.Introduction
Alzheimer’s disease (AD), which is characterized by pro-
gressive deterioration in cognition, function, and behavior,
places a considerable burden on western societies. It is the
sixth leading cause of all deaths and the ﬁfth leading cause
of death in persons aged ≥65 years. To date, an estimated
5.4 million Americans have AD, but due to the baby boom
generation, the incidence in 2050 is expected to reach a
million persons per year, resulting in a total estimated
prevalence of 11 to 16 million aﬀected persons.
Since the ﬁrst description of presenile dementia by Alois
Alzheimer in 1907 [1], senile plaques (SPs) and neuroﬁb-
rillary tangles (NFTs) are considered the key pathological
hallmarks of AD [2]. The identiﬁcation of β-amyloid (Aβ)
in SPs [3] and genetic studies that identiﬁed mutations
in the amyloid precursor protein (APP)[ 4], presenilin 1
(PSEN1), and presenilin 2 (PSEN2)g e n e s[ 5, 6] leading to
the accumulation of Aβ and early-onset familial dementia
[4,5,7], resulted in the formulation of the “Amyloid Cascade
Hypothesis” (ACH; Figure 1)[ 8, 9]. According to the ACH,
the deposition of Aβ is the initial pathological trigger in
the disease, which subsequently leads to the formation
of NFTs, neuronal cell death and dementia. While there
is considerable evidence supporting this hypothesis, there
are observations that seem to be inconsistent. This paper
summarizes the current evidence forand against the amyloid
cascade in AD.
2. Amyloid Cascade Hypothesis
As described above, two key observations resulted in the
original formulation of the ACH (Figure 1). First, the
detection of Aβ as a main constituent of the SPs [3]a n d
second mutations of the APP [4], PSEN1,a n dPSEN2 genes
[5, 6], which were found in families with early-onset AD
(FAD, disease onset < 60 years). As a consequence of these
observations, the presence of Aβ within SPs was interpreted
as an eﬀect of these mutations that subsequently leads to
cell death and dementia. Since FAD has—except the earlier
onset—a similar phenotype to late-onset AD, it was assumed2 International Journal of Alzheimer’s Disease
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Figure 1: Amyloid cascade hypothesis.
that this amyloid deposition could explain the pathogenesis
of all types of AD.
3. Evidence from Studies on the Formation
of Aβ andTau
There are two major objections regarding the ACH as
originally formulated. First, SPs and NFTs may be reactive
products resulting from neurodegeneration in AD rather
than being its cause, and, second, it remains unclear whether
andhowthedepositionofAβ leadstotheformationofNFTs.
3.1. Aβ and Tau as Reactive Processes. In persons who suf-
fered from head trauma, APP is found with pathological
features similar to AD in neuronal perikarya and in dys-
trophic neurites surrounding Aβ deposits [10]. In addition,
there is evidence that neurons in the medial temporal lobe
secrete APP and display increased APP immunoreactivity
[11].TheseﬁndingssuggestthatincreasedexpressionofAPP
in head trauma cases may be an acute-phase response to
neuronal injury [12], which in turn leads to increased Aβ
deposition. This notion is supported by the observation
that the diﬀerent morphological forms of Aβ deposits,
including diﬀuse, primitive, and classic deposits, contain
acute phase proteins such as complement factors and α-anti-
chymotrypsin [13]. Consequently, it has been proposed that,
in AD, APP may be a reaction to the disease process in order
tohelpmaintaincellfunction,neuronalgrowth,andsurvival
[14]. The putative neurotrophic action of APP is supported
by the observation that it shares structural features with the
precursor for epidermal growth factor [14]. Finally, there is
also evidence that NFTs may form as a neuronal response to
injury [15].
There are also ﬁndings from animal studies suggesting
that the formation of Aβ and NFT may be reactive. In rats,
both experimental damage or chemically induced lesions of
the nucleus basalis can elevate cortical APP, and intrathecal
or intraparenchymal injections of toxins can induce APP in
hippocampal neurons, suggesting that the generation of APP
could be a speciﬁc response to loss of functional innervation
ofthecortex[16,17].Denervationofthedopaminepathways
and septal lesions aﬀecting both the cholinergic system
and γ-aminobutyric acid (GABA) neurons projecting to the
dentate gyrus can result in a loss of dendritic microtubule-
associated protein 2 (MAP2) and the appearance of tau-
immunoreactive dentate gyrus granule cells [18]. Thus, den-
ervation can cause transsynaptic changes in dentate gyrus
neurons,andthesealterationsmayrepresentanintermediate
step to NFTs formation.
3.2. Relation of the Formation of NFT to Aβ. SPs and NFTs
cluster in a signiﬁcant proportion of cortical areas but they
seem to be distributed independently of each other [19]. SP
and NFTs also seem to occur temporally separated; in the
entorhinal cortex the occurrence of NFTs may in fact precede
the occurrence of SPs [20]. This spatial and temporal separa-
tion may suggest that they are pathogenically disconnected.
However, evidence for an eﬀect of Aβ on the formation
of NFT comes from transgenic experiments. The presence of
APP mutations alone or in combination with PSEN1 muta-
tions seems to induce Aβ deposits in normal brain and some
degree of hyperphosphorylated tau in neurites [21] although
it does not appear to induce tau pathology or a signiﬁcant
inﬂammatory response. These ﬁndings are consistent with
studies in which fetal rat hippocampal neurons and human
corticalneuronstreatedwithﬁbrielarAβdisplayanincreased
degree of tau phosphorylation [22] providing additional
evidence that amyloid ﬁbril formation might alter the
phosphorylation state of tau, which in turn results in the loss
of microtubule-binding capacity. Other studies showed that
Aβ25−35 can induce the aggregation of tau proteins and that a
decrease in aggregation of Aβ was induced by tau peptides
[23]. Thus, aggregation of tau may be associated with
disassembly of Aβ, which could explain the lack of spatial
correlation of the SPs and NFTs [19]. Finally, the notion of
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APP-transgenic mice reporting that a reduction in endoge-
nous levels of tau can ameliorate some of the behavioral
and other deﬁcits that are mediated by Aβ [24, 25]a n db y
the discovery that mutations in the tau gene cause autosomal
dominant frontotemporal lobe dementia with a tau pathol-
ogy similar to the tau pathology seen in AD but without the
appearanceofAβ plaques[26].Boththeseobservationsseem
to place tau pathology downstream of amyloid-β pathology.
4. Evidencefrom GeneticStudies
In particular the genes identiﬁed in the late-onset form of
the disease provide support for the ACH. In general, these
genesarenotinheritedinaMendelianbutasporadicfashion.
However, ﬁrst-degree relatives of patients with late-onset AD
havetwicetheexpectedlifetimeriskofthisdiseasecompared
to persons without an aﬀected ﬁrst-degree relative, and late-
onset AD is more frequent among monozygotic than dizy-
gotic cotwins, suggesting a substantial genetic contribution
to this form of the disease.
The apolipoprotein E (APOE) gene, which was identiﬁed
as the ﬁrst susceptibility gene for late-onset AD, is the major
genetic risk factor (population attributable risk: ∼20%) [27,
28]. Each APOE-ε4 allele lowers the age at onset in a dose-
dependent fashion [27]. How the diﬀerent APOE proteins
mediate their eﬀects in AD is not fully clariﬁed, but there
is compelling evidence by PDAPP transgenic mice models
indicating that APOE mediates the clearance of amyloid-β
[29], with the APOE2, APOE3, and APOE4 isoforms being
increasingly less eﬀective [30]. Consistent with this notion,
the presence of an APOE-ε4 allele is associated with a higher
Aβ burden in the brains of LOAD patients [31, 32], sug-
gesting that APOE interacts with Aβ by enhancing its depo-
sition in plaques. In various ethnic groups, two haplotypes
in the sortilin-related receptor (SORL1) gene associated with
LOAD were identiﬁed [33–37]. SORL1 is involved in traﬃck-
ing of APP from the cell surface to the golgi-endoplasmic
reticulum complex and γ-secretase processing of APP [34,
38, 39], also in line with the ACH. Recent large-scale GWA
studies performed primarily in samples and populations of
European ancestry detected genetic variants associated
with AD in complement component (3b/4b) receptor 1
(CR1), clusterin (CLU, APOJ), bridging integrator 1
(BIN1), phosphatidylinositol-binding clathrin assembly pro-
tein (PICALM), EPH receptor A1 (EPHA1), CD33 molecule
(CD33), membrane-spanning 4-domains, subfamily A,
members 4 and 6E (MS4A4/MS4A6E), CD2-associated pro-
tein (CD2AP), and ATP-binding cassette, subfamily A, mem-
ber 7 (ABCA7)[ 40–42]. While these genes remain to
undergo functional validation, they are functionally plausi-
ble and also largely consistent with the ACH. Similar and
additive to APOE, CLU encodes an apolipoprotein and acts
as an Aβ chaperone, regulating the conversion of Aβ to
insoluble forms and Aβ toxicity thereby promoting amyloid
plaque formation [43]. ABCA7 is involved in the eﬄux of
lipids from cells to lipoprotein particles, such as APOE and
CLU, and in addition regulates APP processing and inhibits
β-amyloid secretion [44]. There is evidence that CR1 may
contribute to Aβ clearance by complement activation [45].
CD2AP, CD33, BIN1, and PICALM are involved in endo-
cytosis (CME), and a recent study [46] showed that several
of these factors involved in endocytosis modify Aβ toxicity
in glutamatergic neurons of Caenorhabditis elegans and in
primary rat cortical neurons. In yeast, Aβ impaired the
endocytic traﬃcking of a plasma membrane receptor, which
was ameliorated by endocytic pathway factors identiﬁed in
the yeast screen also providing substantial evidence for a link
between Aβ, endocytosis, and human AD [46]. In summary,
convincing evidence for an Aβ-related mechanism exists for
all of these identiﬁed LOAD genes, providing a substantial
amount of support for the ACH in AD.
5. Evidencefrom ClinicalTrialsTargeting
Aβ andTau
The drugs currently used to treat AD (i.e., cholinesterase
inhibitors, NMDA receptor antagonists, and antipsychotic
drugs) have limited therapeutic value. New, potentially
disease-modifying, therapeutic approaches are targeting Aβ
and tau protein. Driven by the ACH, there are currently four
main therapeutic approaches: (a) reducing the generation of
Aβ, (b) facilitating the clearance of Aβ, (c) preventing the
aggregation of Aβ and destabilizing Aβ oligomers, and (d)
drugs targeting tau [47]. Drugs classes include active and
passive immunization directed against Aβ, compounds that
interfere with the secretases regulating Aβ generation from
APP, drugs to prevent Aβ aggregation and destabilize Aβ
oligomers, and drugs targeting tau protein.
5.1. Active and Passive Immunization. Active and passive
immunizations were developed to inhibit generation of toxic
Aβ aggregates and to remove soluble and aggregated Aβ.
At least three diﬀerent immune-mediated mechanisms can
promote Aβ removal: solubilization by antibody binding to
Aβ, phagocytosis of Aβ by microglia, and Aβ extraction from
the brain by plasma antibodies.
In phase II randomized controlled trials (RCTs) of active
immunization of patients with mild-to-moderate AD with
the anti-Aβ vaccine AN-1792 (QS-21) most but not all
participantsdevelopedsigniﬁcantAβ-antibodytitres[48,49]
and there was evidence of memory and function improve-
ment and reduced CSF tau concentrations in patients with
increased IgG titres [48, 49]. However, in the ﬁrst trial
patients immunized with AN-1792 had a greater brain
atrophy rate on MRI than did patients given placebo possibly
because of amyloid removal and cerebral ﬂuid shifts. In
addition, several patients developed meningoencephalitis
due to a T-cell response. In the follow-up trial, brain volume
loss in antibody responders was not diﬀerent from that in
patients receiving placebo, and no further cases of menin-
goencephalitis were found [49]. Responders maintained low,
but detectable, anti-AN-1792 antibody titres at about 4.6
yearsafterimmunizationandhadsigniﬁcantlyreducedfunc-
tional decline compared with placebo-treated patients [49].
In addition, immunization with anti-AN-1792 antibody
could completely remove amyloid plaques as determined by4 International Journal of Alzheimer’s Disease
postmortem assessment although patients still had end-stage
dementia symptoms before death.
In order to avoid neuroinﬂammation and neurotoxicity,
new vaccines that selectively target B-cell epitopes have been
developed. CAD-106, which consists of the immunodrug
carrier Qb coupled with a fragment of the Aβ1−6 peptide,
could in animal studies induce Aβ-speciﬁc antibodies and
reduce amyloid accumulation without stimulating T cells.
In patients with mild-to-moderate AD, CAD-106 induced
a substantial anti-Aβ IgG response and was well tolerated
[50], conﬁrmatory phase II RCTs are ongoing (NCT01097
096, NCT01023685, NCT00795418, NCT00956410, and
NCT00733863).ACC-001isanAβ1−6 fragmentderivedfrom
the N-terminal B cell epitope of Aβ and conjugated to
the mutated diphtheria toxin protein CRM19. It is being
studied in phase II RCTs (NCT00479557, NCT01284387,
NCT01227564, NCT00498602, NCT00752232, NCT00955
409, NCT01238991, NCT00960531, NCT00959192). ACI-
24 is a vaccine that contains Aβ1−15 closely apposed to the
surface of the liposome. It reduced brain amyloid load and
restored memory deﬁcits in mice [51] and is entering a phase
II RCT. Vaccines that are currently being tested in phase I
RCTs are V-950 (NCT00464334; an aluminium-containing
adjuvant with or without ISCOMATRIX (CSL Behring, PA,
USA, a biological adjuvant of saponin, cholesterol, and
phospholipids) and UB-311 (NCT00965588), a vaccine in
which the immunogen Aβ1−14 is associated with the UBITh
peptide (United Biomedical, NY, USA) and a mineral salt
suspension adjuvant [52].
Aﬃtopes, which are short peptides mimicking parts of
native Aβ1−42, represent an alternative active immunization
strategy. The aﬃtopes AD-01 and AD-02 target the N-
terminalAβ fragmentandbothhaddisease-modifyingprop-
erties in animal models of AD [53]. Results of recent phase
I RCTs indicate that both are safe and well tolerated
(NCT00495417, NCT00633841, and NCT00711139) [53].
AﬃtopeAD-02recentlyprogressedtophaseIIclinicaltesting
(NCT01117818).
Passive immunotherapy is based on monoclonal anti-
bodies or polyclonal immunoglobulins targeting Aβ to
promote its clearance. Animal studies have shown that
anti-Aβ antibodies can prevent oligomer formation and
reduce brain amyloid load with improvement in cognitive
functions [54]. Several monoclonal antibodies are cur-
rently being tested: bapineuzumab (AAB-001), solanezumab
(LY-2062430), PF-04360365, GSK-933776, R-1450 (RO-
4909832), and MABT-5102A. A phase II RCT of bapin-
euzumab in patients with mild-to-moderate AD that had
a follow-up period of longer than 18 months reported no
signiﬁcant eﬀects on the primary measures of cognition
or activities of daily living, as measured in prespeciﬁed
within-dose cohort analyses. However, post hoc anal- yses
of clinical and neuroimaging data from all dose cohorts
showed nonsigniﬁcant improvements in cognitive end-
points and signs of eﬃcacy in APOE ε4 noncarriers [55].
Phase III studies are ongoing, including separate RCTs
for APOE ε4 carriers and non-carriers (NCT00574132,
NCT00996918, NCT00998764, NCT00667810, NCT005
75055, NCT00676143, and NCT00937352). Solanezumab,
a monoclonal antibody that targets speciﬁcally soluble Aβ,
promotes Aβ clearance from the brain through the blood. In
a phase II RCT, there was a correlation between total plasma
Aβ1−42 after treatment (dose-dependent increase), baseline
amyloid plaque burden shown by single-photon emission
CT scanning, and a dose-dependent increase in unbound
CSF Aβ1−42, suggesting that solanezumab might mobilize
Aβ1−42 from plaques and might normalize soluble CSF
Aβ1−42 in patients with AD [56]. Consequently, two phase
III RCTs have been initiated (NCT00905372, NCT00904683,
NCT01127633). PF-04360365 is a modiﬁed IgG2 antibody
that binds to the C terminus of Aβ1−40. Preliminary results
on a single-dose regimen indicate that this antibody is well
tolerated in patients with AD [57]. Currently, two phase
II RCTs of multiple doses are ongoing (NCT00722046 and
NCT00945672). GSK-933776, R-1450 (RO-4909832), and
MABT-5102A are monoclonal antibodies that target Aβ and
have been tested in patients with AD in phase I and phase
II trials (NCT01424436, NCT00459550, NCT01224106,
NCT00531804, NCT00736775, NCT00997919, NCT0134
3966, and NCT01397578).
Passive immunization [58] can also be achieved by
intravenous infusion of immunoglobulins (IVIg), from
healthydonors,whichincludenaturallyoccurringpolyclonal
anti-Aβ antibodies. IVIg is already approved as therapy
for immune deﬁciency, with good safety and tolerability
evidence. In two small studies, short-term immunoglobulin
administration in patients with AD was well tolerated,
promoted a decrease of total Aβ CSF concentrations, and
increased plasma total Aβ concentrations [59, 60], with
evidence of improvement or stabilization of cognitive func-
tions. Preliminary data from a phase II RCT conﬁrmed
the positive eﬀects on cognition [61], a phase III study is
ongoing (NCT00818662). In summary, the RCTs on active
and passive immunization agents consistently show an eﬀect
on amyloid clearance, and several but not all phase II RCTs
show promising eﬀects on cognition.
5.2. Drugs to Reduce Aβ Generation from APP. BACE1 (β-
secretase) initiates the amyloidogenic pathway. Pioglitazone
and rosiglitazone are thiazolidinediones and drugs com-
monly used to treat type II diabetes. They happen to act as
BACE1 inhibitors through stimulating the nuclear peroxi-
some proliferator-activated receptor γ (PPARγ). Activation
of PPARγ receptors, in turn, can suppress expression of
BACE1 and APP and can promote APP degradation by
increasing its ubiquitination [62]. In addition to their eﬀects
onBACE1,therapeuticeﬀectsofPPARγ agonistsinADcould
be caused by their eﬀect on insulin action. Both rosiglitazone
and pioglitazone increase peripheral insulin sensitivity and
reduce concentrations of insulin. Insulin, in turn, competes
with Aβ for degradation by the insulin-degrading enzyme
[62].
There are only few phase III RCTs, which likely reﬂects
the diﬃculty in development of BACE1 targeting agents.
BACE1 has many substrates including several with phys-
iologically important functions such as neuregulin-1 that
is involved in myelination, and drugs must cross the
blood-brain barrier in order to modulate BACE1 function.International Journal of Alzheimer’s Disease 5
Pioglitazone can cross the blood-brain barrier although
whether rosiglitazone can reach the CNS in human beings is
unclear[62].OutoftheRCTsthathaveexploredtheeﬀectsof
pioglitazone and rosiglitazone on cognition in patients with
AD or MCI (NCT00982202, NCT00736996, NCT00550420,
NCT00428090, NCT00348309, NCT00242593, NCT00265
148, NCT00348140, NCT00334568, and NCT00490568),
only three (NCT00982202, NCT00428090, and NCT002651
48) have reported results to date, and these were negative
[63]. Currently, several new β-secretase inhibitors are under
investigation. Of these, CTS-21166, an orally administered
compound, was well tolerated and reduced plasma Aβ
concentrations in mice [64] and has proceeded to phase I
clinical testing [65].
Development of drugs targeting γ-secretase, the enzyme
responsible for the ﬁnal step in Aβ generation, presents
challenges similar to those for β-secretase inhibitors as γ-
secretase is one of the main complexes involved in intram-
embranous cleavage of several proteins, including APP,
Notch receptor, and various neuronal substrates [66]. As a
consequence, adverse eﬀects of γ-secretase inhibitors include
hematological and gastrointestinal toxicity, skin reactions,
and changes to hair color, mainly caused by inhibition
of the Notch signaling pathway, which is involved in cell
diﬀerentiation.
Phase III trials for the Notch-inhibiting drug semagace-
stat failed. Preliminary ﬁndings showed that semagacestat
not only failed to slow disease progression, but also was
associated with worsening of clinical measures of cognition
and the ability to perform activities of daily living and a
higher incidence of skin cancer in the treatment group
than the placebo group. However, several Notch-sparing γ-
secretase inhibitors (second-generation inhibitors) are cur-
rently under development: begacestat was tested in a phase
I RCT (NCT00959881) and BMS-708163 in two phase II
RCTs in patients with prodromal or mild-to-moderate AD
(NCT00810147 and NCT00890890). Begacestat reduced Aβ
concentrations in the plasma (with delayed rebound) [67]
but did not substantially aﬀect CSF Aβ1−40, whereas BMS-
708163 promoted a dose-dependent decrease of Aβ1−40 in
theCSF[68].ResultsfromanimalstudiestestingPF-3084014
showed decreases in Aβ in the plasma, CSF, and brain,
without a rebound eﬀect on plasma Aβ [69]. In a subsequent
small phase I study, PF-3084014 promoted a dose-dependent
reduction in plasma Aβ concentrations although eﬀects on
CSF concentrations were small [70]. NIC5–15, a naturally
occurring monosaccharide found in many foods, can act as
a Notch-sparing γ-secretase inhibitor and insulin sensitizer
(i.e., it increases the sensitivity of the tissue to insulin). It is
currently being tested in patients with AD in a phase II study
(NCT00470418).
γ-secretase modulators can selectively block APP pro-
teolysis without Notch-based adverse eﬀects. A subset of
nonsteroidal anti-inﬂammatory drugs (NSAIDs), including
ibuprofen, indomethacin, and sulindac sulﬁde, bind to APP
and act as γ-secretase modulators, decreasing Aβ1−40 and
Aβ1−42 production, with increased generation of Aβ1−38
fragments. Among these compounds, known as selective
β-amyloid-lowering agents (SALAs), tarenﬂurbil was tested
in phase III RCTs in patients with mild AD but did not
show clinical eﬀects [71] possibly due to low γ-secretase
modulator potency, poor CNS penetration, or inhibition
of microglia-mediated Aβ clearance by residual NSAID
activity. Another γ-secretase modulator, CHF-5074, reduced
Aβ brain load and improved behavioral deﬁcits in animals
[72] and has reached phase II clinical testing (NCT01303744
and NCT01421056).
Upregulation of α-secretase activity, leading to non-
amyloidogenic cleavage of APP, can decrease Aβ formation
and increase production of a potentially neuroprotective
soluble domain (sAPPα)[ 73]. Several drugs can stimulate α-
secretase (agonists of muscarinic, glutamate, and serotonin
receptors; statins; oestrogens; testosterone; protein kinase
C activators) and have been tested in clinical trials, but
no conclusive results are available yet [74]. These α-
secretase modulators include Exebryl-1, which modulates
β-a n dα-secretase activity causing substantial reduction
of Aβ formation and accumulation in the mouse brain
with memory improvements (a phase I RCT was approved
in 2008) [75], Etazolate (EHT-0202), a selective GABAA
receptor modulator that stimulates neuronal α-secretase and
increases sAPPα production [76] and has been recently
tested in a phase II RCT in patients with mild-to-moderate
AD (NCT00880412) [77], and Bryostatin-1, a macrocyclic
lactone that can stimulate α-secretase by activating protein
kinase C and promoting sAPPα secretion [78] reducing
brainAβ1−40 andAβ1−42 andimprovingbehavioraloutcomes
i nm o u s em o d e l so fA D[ 78] (phase II study in process
(NCT00606164)).
5.3. Drugs to Prevent Aβ Aggregation and Destabilize Aβ
Oligomers. Compounds that inhibit Aβ aggregation or
destabilize Aβ oligomeric species can act twofold: (a) either
they bind to Aβ monomers thereby preventing oligomeriza-
tion and allowing Aβ elimination, or (b) they react with Aβ
oligomers thereby neutralizing their toxicity and promoting
their clearance. They are chemically heterogeneous and also
here the challenge is to develop agents that can cross the
blood brain barrier and have low toxicity.
The ﬁrst generation of nonpeptidic antiaggregates failed
to fulﬁll these criteria. Tramiprosate (3APS), which main-
tains Aβ in the nonﬁbrillar state by binding to soluble
form, showed negative results in the Alphase study, a phase
III RCT [79] although previous experimental and phase
II trials had been promising [80]. Although there are
several possible reasons for this failure, including variability
among study sites, diﬀerences in the treatment and control
groupsbecauseoftheconcomitanttreatmentwithcognitive-
enhancing drugs, and low CNS bioavailability of the drug, a
European phase III RCT with tramiprosate was terminated
as a consequence of the negative ﬁndings.
Clioquinol (PBT1) inhibits Aβ aggregation through
interfering with interactions between Aβ, copper, and zinc.
Studies in Tg2576 mice and human volunteers showed that
CQ entry into the brain is limited although upon brain
entry it binds to amyloid plaques [81]. PBT1 showed positive
results in phase II RCTs but further phase II/III studies6 International Journal of Alzheimer’s Disease
were halted due to manufacturing toxicity issues [82]. The
second-generation inhibitor, PBT2, has a greater blood-
brain barrier permeability than does clioquinol, and animal
experiments showed that PBT2 prevents Aβ oligomerization,
promotes Aβ oligomer clearance, reduces soluble and insol-
uble brain Aβ, decreases plaque burden, and has positive
eﬀects on cognition [82]. A 12-week, phase II RCT in
patients with mild AD, was consistent with these ﬁndings,
PBT2 reduced Aβ1−42 CSF concentrations and improved
executive function [83]. Scyllo-inositol (ELND-005) is an
orallyadministeredstereoisomerofinositolthatcancrossthe
blood-brain barrier using inositol transporters. By binding
to Aβ, it modulates its misfolding, inhibits its aggregation
and stimulates dissociation of aggregates. It was successful in
animal studies, reducing brain concentrations of soluble and
insoluble Aβ1−40 and Aβ1−42, plaque burden, synaptic loss,
and glial inﬂammatory reaction and signiﬁcantly improving
spatial memory function [84]. It is currently being tested in
phaseIIRCTs(NCT00568776andNCT00934050).However,
because of serious adverse events among patients in the
two high-dose groups (1000mg and 2000mg twice daily),
these doses have been removed from the RCT, and the study
continues restricted to patients who are assigned the lower
dose (250mg twice daily) and placebo. Epigallocatechin-
3-gallate (EGCg), a polyphenol from green tea, induces
α-secretase and prevents Aβ aggregation in animals by
directly binding to the unfolded peptide [85]. In addition, it
modulates signal transduction pathways, expression of genes
regulating cell survival and apoptosis, and mitochondrial
function [85]. It is currently being tested in a phase II/III
RCT in patients with early AD.
5.4. Drugs to Target Tau Protein. Tau is a cytoplasmatic pro-
tein that binds to tubulin during its polymerisation, stabilis-
ing microtubules. In AD, tau is abnormally phosphorylated,
resulting in the generation of aggregates (neuroﬁbrillary
tangles) toxic to neurons. The hypothesis that tau pathology
causes AD has been the main competitor of the amyloid
hypothesis [86]. However, only one tau-directed compound
(valproate; valproic acid) has so far reached phase III RCT,
with disappointing results because there were no eﬀects on
cognition and functional status [87].
There are two main therapeutic approaches to target
the tau protein: modulation of tau phosphorylation with
inhibitors of tau-phosphorylating kinases and compounds
that inhibit tau aggregation and/or promoting aggregate
disassembly. The ﬁrst approach is based on the observation
that tau hyperphosphorylation and neuroﬁbrillary tangle
formationcanbepromotedbyimbalancedactivityofprotein
kinases (glycogen-synthase-kinase-3 (GSK3) and p70-S6-
kinase) and the phosphatase PP2A [88]. GSK3 deregulation
might have a role in AD pathogenesis because GSK3 is
involved in tau and amyloid processing, cellular signaling,
and gene transcription [88].
Bothlithiumandvalproate,wellknownforthetreatment
of psychiatric disorders, inhibit GSK3,to reduce tau phos-
phorylation and prevent or reverse aspects of tauopathy in
animal models [89]. Both drugs can also be neuroprotective
by upregulating the antiapoptotic factor BCL2, inducing
neurotrophic factors, and hindering Aβ toxicity [89]. How-
ever, a small RCT with lithium (10 weeks, including a 6-week
titration phase) in patients with mild AD did not show any
cognitive beneﬁtor anychangein CSF biomarkers,including
phosphorylated tau, total tau, and Aβ1−42 [90].
The AD Cooperative Study (ADCS) of valproate was
designed to determine whether chronic valproate treatment
could delay the onset of behavioral symptoms in outpatients
with mild-to-moderate AD; a secondary aim was to test
whethervalproatecandelaycognitiveandfunctionaldecline.
No eﬀects on cognition and functional status were reported,
but incidence of agitation and psychosis seemed to be
reduced [89].
Several GSK3 inhibitors are under development. NP-
031112 (NP-12) is a thiadiazolidinone-derived compound, a
non-ATP competitive inhibitor of GSK3, which can reduce
brain concentrations of phosphorylated tau and amyloid
deposition and prevent neuronal death and cognitive deﬁcits
in animals [91]. This drug has been tested in patients with
AD in a phase II RCT (NCT00948259); no results have yet
been published.
Methylthioninium chloride (methylene blue), a widely
used histology dye, acts as a tau antiaggregate [92]. This
compound also has antioxidant properties, enhances mito-
chondrial function [93], and was eﬀective, alone and in
combination with rivastigmine, in reversing learning deﬁcits
andhyoscine-inducedmemoryimpairmentsinanimals[94].
Diﬀerentdosesofmethylthioniniumchloride(upto100mg)
were tested in a phase II study in patients with moderate
AD. The group given the 60mg dose had improved cognitive
function and, after 1 year, evidence of slower disease
progression compared with placebo [95]. The ineﬀectiveness
in the group on the 100mg dose was attributed to drug
formulation defects, limiting release. A new formulation
(leuco-methylthioninium), with a higher bioavailability, was
recently announced [96], and phase III RCTs are needed to
conﬁrm its safety and clinical eﬃcacy.
Davunetide (AL-108, NAP), an intranasally adminis-
tered, eight-aminoacid peptide fragment derived from the
activity-dependent neuroprotective protein, and AL-208, an
intravenousformulationofDavunetide,arebeingdeveloped.
Davunetide has been tested in animal models of AD and
tauopathy, and its neuroprotective activity includes regula-
tion of microtubule dynamics, as well as inhibition of tau
hyperphosphorylation and protection against Aβ toxicity
[97, 98]. Davunetide was studied in patients with amnestic
mild cognitive impairment in a 12-week, phase II RCT
and was safe and well tolerated and had positive eﬀects on
cognition [99], although conﬁrmatory studies are needed.
Nicotinamide is the biologically active form of niacin
(vitamin B3) and the precursor of coenzyme NAD+. Orally
administered nicotinamide canprevent cognitive deﬁcitsin a
mousemodelofADandcanreducebrainconcentrationsofa
species of phosphorylated tau (Thr231) that inhibits micro-
tubule polymerization [100]. Furthermore, nicotinamide
inhibits brain sirtuin deacetylase and upregulates acetyl-α-
tubulin, protein p25, and MAP2c; all these interactions are
associated with increased microtubule stabilization [100].
Nicotinamide has been used in several clinical studies,International Journal of Alzheimer’s Disease 7
Table 1: Issues of RCTs of AD.
Issue Possible solution
Subjects
Target group selection: patients with AD have various types of
neuropathology (i.e., amyloid plaques, NFTs, infarcts, and Lewy
bodies)
Criteria for identifying subgroups with more homogeneous biomarker
evidence of AD pathology are needed to facilitate RCTs
In patients with mild-to-moderate AD, the disease could be too
advanced for a disease-modifying eﬀect of a speciﬁc drug (e.g.,
immunotherapy)
RCTs that include patients with early AD might enable detection of
disease-modifying eﬀects; investigation into which stage of the AD
process a therapeutic strategy is more eﬀective is warranted
Agents
Choosing the right drug: compounds with positive results in
preclinical and early clinical testing failed in large phase III
RCTs, with costly losses (e.g., tramiprosate)
Robust proof-of-concept studies should be mandatory
Investigators should take into account class eﬃcacy
Use of drug-related biomarkers in preclinical and early clinical stages
can help to conﬁrm the target engagement and to assure early
withdrawal of ineﬀective drugs
Some RCTs were likely hindered by the inability to reach a
therapeutic dosage (e.g., tarenﬂurbil) or short treatment
duration
Optimization of drug dosage and treatment duration based on
pharmacokinetics
Genetics: polymorphisms (e.g., APOE,) might aﬀect drug
response
Personalized therapeutic approach: considering genetic polymorphisms
that aﬀect drug response can help to optimize drug dosage (e.g.,
increased doses for individuals with a rapid metabolism)
Outcome measurements
Measuring eﬀects: many RCTs are developed according to the
design of AChEI RCTs, an approach that has indicated the
AChEI symptomatic eﬀect but is not sensitive in detecting the
eﬃcacy of disease-modifying drugs, rating scales used may have
low sensitivity for changes and/or the drug type assessed and
these tools have a subjective component
Development and use of relevant, reliable, multidimensional measures
for clinical (cognitive and functional) endpoints are key factors, as well
the use of biomarkers (neuroimaging, CSF, or blood molecules) that
reliably and quantitatively correlate with disease progression; collection
of baseline data (clinical, biomarkers) that can be used as reference to
interpret later ﬁndings is advisable; for early AD (i.e., mild cognitive
impairment), self-rated and observer-rated assessments of activities of
daily living, instrumental activities of daily living, and quality of life are
recommended
Unreliable evaluation of patients by RCT raters
Adequate training and monitoring of RCT raters to maximize
homogeneous recruitment of patients, reduce variance, and guarantee a
more accurate rating; eﬀective implementation of quality control on
data at research sites
Optimization of resources
Consistency: multicenter RCTs done in several countries can
have cultural and linguistic issues with assessment scales (e.g.,
translation, validation), as well as infrastructure problems
(technological disparities between centers)
Multicenter trials should use centers of excellence that are already
experienced in RCTs to minimize intersite and intercountry variability
Unsuccessful preclinical and clinical studies are often not
published leading to repetition of unsuccessful trials or errors
More collaboration between pharmaceutical companies and clinical
researchers, with information sharing, can lead to more standardized
RCT protocols, reduction of errors, and decreased costs
including RCTs in patients with neurodegenerative disor-
ders, and is generally safe and well tolerated; a phase II
RCT is ongoing in patients with mild-to-moderate AD
(NCT00580931).
What do these trials tell us? Sadly, they leave little
certainty. Amyloid immunization teaches us that we can
massively reduce amyloid burden, but when administered
late in the disease, it is not a miracle cure. It may have
clinically relevant beneﬁts and it may lead to better outcomes
ifit is givenearly inthe disease orpresymptomatically butwe
simply do not have data to address these issues.
6. Conclusions
Overall, there is substantial evidence supporting a role of the
ACH in AD. However, the available results from RCTs are
not in line with previous optimistic predictions of an immi-
nent breakthrough in development of a disease-modifying
therapy. To explain the disappointing results of several RCTs,
researchers have highlighted various potential issues, both in
drug choice and development programs. Table 1 summarizes
these and provides possible solutions. Clinical trials need to
be organized in those in the very earliest stages of the disease.
Whether this can be carried out genetically (e.g., by using
E4 homozygotes) or by PIB imaging or some combination8 International Journal of Alzheimer’s Disease
of both is not clear. Of course, it could be argued that even
persons who show PIB signals are already too far down
the disease progression for disease-modifying therapy and
that treatment needs to be initiated even before this stage.
Certainly, even those with mild AD have profound cell loss.
In addition, it would be helpful to perform antiamyloid
trials in individuals with APP and PSEN mutations or those
with Down’s syndrome as they provide the best test of the
ACH hypothesis. Biomarker studies should be included in
trial designs so that the researchers can form, as clearly as
possible, informed opinions as to whether the drug has hit
the proposed target.
However, in addition to implementing new guidelines in
preclinical and clinical phases of drug development, several
additional issues are key to validate the ACH and successfully
develop therapeutic targets. From a molecular point of view,
we need a focused eﬀort to fully understand the functions
of APP and Aβ and to answer the two key questions:
does Aβ in fact inﬂuence tau phosphorylation and, if yes,
does tau phosphorylation in fact lead to dementia? Second,
we need to understand the nature of disease propagation:
is permissive templating of Aβ [101, 102]a n dt a u[ 103]
the reason for both the characteristic neuroanatomy of
the disease [104] and the reason that the disease seems
to become self-propagating once it has started [105, 106]?.
Finally, it makes sense to pursue other targets beyond Aβ
as there is substantial evidence for additional potential
pathways increasing disease susceptibility, among these lipid
metabolism and inﬂammatory processes [107].
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